Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
<p>Abstract</p> <p>Background</p> <p>Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m<sup>2 </sup>and 100 mg/m<sup>2</sup>) or weekly regimens (35–40 mg/m<sup>2</sup>). The pharmacokinetics and radios...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-10-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/7/197 |
| _version_ | 1818783194799931392 |
|---|---|
| author | Kristensen Vessela Aamdal Steinar Andersen Anders Fr Brunsvig Paal Olsen Harald |
| author_facet | Kristensen Vessela Aamdal Steinar Andersen Anders Fr Brunsvig Paal Olsen Harald |
| author_sort | Kristensen Vessela |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m<sup>2 </sup>and 100 mg/m<sup>2</sup>) or weekly regimens (35–40 mg/m<sup>2</sup>). The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m<sup>2 </sup>docetaxel, has however not been well characterized. We examined the pharmacokinetics of weekly docetaxel when administered with concurrent radiotherapy and compared the results with a 3-weekly 100 mg/m<sup>2 </sup>regimen.</p> <p>Methods</p> <p>Thirty-four patients with non small cell lung cancer (NSCLC) were included in this study, 19 receiving 100 mg/m<sup>2 </sup>docetaxel 3-weekly as single therapy, and 15 receiving 20 mg/m<sup>2 </sup>docetaxel weekly with concurrent radiotherapy. A newly developed HPLC method was used for measuring docetaxel levels, capable of quantifying docetaxel in plasma down to the nanomolar level.</p> <p>Results</p> <p>The HPLC method showed detectable concentrations of docetaxel in plasma even after 72 hours. In the present study we have demonstrated that median docetaxel plasma levels of 3 nM can be obtained 72 hours after a dose of 20 mg/m<sup>2</sup>.</p> <p>Conclusion</p> <p>The pharmacokinetics of docetaxel is characterized by great inter-individual variability and at some time points plasma concentrations for 20 mg/m<sup>2 </sup>and 100 mg/m<sup>2 </sup>docetaxel were overlapping. Extrapolation of these results indicates that radio sensitizing docetaxel concentrations may be present for as long as 1 week, thus supporting the use of 20 mg/m<sup>2 </sup>weekly docetaxel.</p> |
| first_indexed | 2024-12-18T13:00:19Z |
| format | Article |
| id | doaj.art-bd39fbfcc00b47f59d6335459699c6ce |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-18T13:00:19Z |
| publishDate | 2007-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-bd39fbfcc00b47f59d6335459699c6ce2022-12-21T21:07:09ZengBMCBMC Cancer1471-24072007-10-017119710.1186/1471-2407-7-197Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapyKristensen VesselaAamdal SteinarAndersen AndersFr Brunsvig PaalOlsen Harald<p>Abstract</p> <p>Background</p> <p>Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m<sup>2 </sup>and 100 mg/m<sup>2</sup>) or weekly regimens (35–40 mg/m<sup>2</sup>). The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m<sup>2 </sup>docetaxel, has however not been well characterized. We examined the pharmacokinetics of weekly docetaxel when administered with concurrent radiotherapy and compared the results with a 3-weekly 100 mg/m<sup>2 </sup>regimen.</p> <p>Methods</p> <p>Thirty-four patients with non small cell lung cancer (NSCLC) were included in this study, 19 receiving 100 mg/m<sup>2 </sup>docetaxel 3-weekly as single therapy, and 15 receiving 20 mg/m<sup>2 </sup>docetaxel weekly with concurrent radiotherapy. A newly developed HPLC method was used for measuring docetaxel levels, capable of quantifying docetaxel in plasma down to the nanomolar level.</p> <p>Results</p> <p>The HPLC method showed detectable concentrations of docetaxel in plasma even after 72 hours. In the present study we have demonstrated that median docetaxel plasma levels of 3 nM can be obtained 72 hours after a dose of 20 mg/m<sup>2</sup>.</p> <p>Conclusion</p> <p>The pharmacokinetics of docetaxel is characterized by great inter-individual variability and at some time points plasma concentrations for 20 mg/m<sup>2 </sup>and 100 mg/m<sup>2 </sup>docetaxel were overlapping. Extrapolation of these results indicates that radio sensitizing docetaxel concentrations may be present for as long as 1 week, thus supporting the use of 20 mg/m<sup>2 </sup>weekly docetaxel.</p>http://www.biomedcentral.com/1471-2407/7/197 |
| spellingShingle | Kristensen Vessela Aamdal Steinar Andersen Anders Fr Brunsvig Paal Olsen Harald Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy BMC Cancer |
| title | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| title_full | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| title_fullStr | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| title_full_unstemmed | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| title_short | Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| title_sort | pharmacokinetic analysis of two different docetaxel dose levels in patients with non small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy |
| url | http://www.biomedcentral.com/1471-2407/7/197 |
| work_keys_str_mv | AT kristensenvessela pharmacokineticanalysisoftwodifferentdocetaxeldoselevelsinpatientswithnonsmallcelllungcancertreatedwithdocetaxelasmonotherapyorwithconcurrentradiotherapy AT aamdalsteinar pharmacokineticanalysisoftwodifferentdocetaxeldoselevelsinpatientswithnonsmallcelllungcancertreatedwithdocetaxelasmonotherapyorwithconcurrentradiotherapy AT andersenanders pharmacokineticanalysisoftwodifferentdocetaxeldoselevelsinpatientswithnonsmallcelllungcancertreatedwithdocetaxelasmonotherapyorwithconcurrentradiotherapy AT frbrunsvigpaal pharmacokineticanalysisoftwodifferentdocetaxeldoselevelsinpatientswithnonsmallcelllungcancertreatedwithdocetaxelasmonotherapyorwithconcurrentradiotherapy AT olsenharald pharmacokineticanalysisoftwodifferentdocetaxeldoselevelsinpatientswithnonsmallcelllungcancertreatedwithdocetaxelasmonotherapyorwithconcurrentradiotherapy |